Investigating how IL-33 affects immune responses to cancer therapy
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
['FUNDING_R01'] · HACKENSACK UNIVERSITY MEDICAL CENTER · NIH-11084478
This study is looking at how a protein called IL-33, which is usually found in healthy tissues but lower in some tumors, might help make cancer treatments work better by boosting the immune system's response, and it's for people who are interested in improving outcomes from cancer therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HACKENSACK UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (HACKENSACK, UNITED STATES) |
| Trial ID | NIH-11084478 on ClinicalTrials.gov |
What this research studies
This research explores the role of IL-33, a protein that is normally present in healthy tissues but is reduced in certain tumors, in enhancing the effectiveness of immune checkpoint blockade cancer therapy. By analyzing tumor samples and using mouse models, the study aims to understand how IL-33 influences immune cell organization and response to treatment. The researchers will investigate the mechanisms by which IL-33 can potentially improve patient outcomes in cancer therapy, focusing on its interaction with immune cells like dendritic cells and CD8+ T cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-grade tumors who are undergoing or considering immune checkpoint blockade therapy.
Not a fit: Patients with low-grade tumors or those not receiving immune checkpoint blockade therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment strategies that enhance the effectiveness of existing therapies.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar mechanisms, indicating potential for success in this approach.
Where this research is happening
HACKENSACK, UNITED STATES
- HACKENSACK UNIVERSITY MEDICAL CENTER — HACKENSACK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LU, BINFENG — HACKENSACK UNIVERSITY MEDICAL CENTER
- Study coordinator: LU, BINFENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy